Dupixent Improved Quality of Life in Chronic Hives Trials, Analysis Shows

A pooled analysis of two phase 3 trials found that 74.3 percent of chronic spontaneous urticaria patients taking Dupixent (dupilumab) reported that swelling of their eyes and lips did not bother them at all, compared with 60 percent of those on placebo. The figure anchors a new quality-of-life analysis presented at the 2026 European Academy of Dermatology and Venereology Congress and reported by HCPLive.

The analysis covered adults and adolescents with chronic spontaneous urticaria (CSU) who had not previously tried the biologic omalizumab (Xolair). Researchers pooled results from the LIBERTY-CSU CUPID A and C trials over 24 weeks.

What did the trials measure?

Participants taking Dupixent reported greater improvements on a hives-specific quality-of-life questionnaire than those on placebo. The questionnaire captured several dimensions of daily life:

• itch;
• the physical limits that hives place on everyday activities;
• how self-conscious patients feel about their skin.

The swelling result stood out: nearly three in four Dupixent patients — 74.3 percent — said swelling of the eyes and lips did not bother them at all, versus 60 percent of the placebo group, a gap of 14.3 percentage points.

Why the researchers frame it as a quality-of-life story

Chronic hives affect far more than the skin, according to the source report, which described the condition as visible welts, sleepless nights and a constant urge to scratch.

"CSU is a disease that can greatly impact a person's quality of life because of things like feelings of embarrassment due to visible hives or not being able to sleep because of persistent itch," said Thomas B. Casale, MD, a professor of medicine and pediatrics at the University of South Florida Morsani College of Medicine and lead author of the analysis.

His comment frames the analysis around outcomes that patients weigh daily — sleep, embarrassment, participation in life — rather than lesion counts alone.

How strong is the evidence?

The analysis carries clear limits. It was a post hoc analysis, meaning researchers examined the data after the trials had concluded rather than testing pre-specified hypotheses. Some measures, including the overall swelling score and sleep, did not reach statistical significance. The source report characterizes the overall picture as still taking shape.

Sanofi and Regeneron, which make Dupixent, sponsored the trials.

Dupixent is already FDA-approved to treat CSU in people 12 and older, so the analysis does not change the drug's regulatory status. What it adds is patient-reported evidence that symptom relief may extend into how people sleep, move and feel about their appearance.

For dermatologists and allergists, the data reinforce that clearer skin is only part of the treatment goal: patients whose hives disrupt sleep or make them withdraw from daily life should raise those concerns when choosing a therapy, because how they feel day to day matters.